Over a month and a half before the World Health Organization officially declared a pandemic, BioNTech CEO Uğur Şahin met with his wife, BioNTech’s co-founder and chief medical officer Özlem Türeci, and together they agreed to redirect most of the company’s resources to developing a vaccine. Up until that point, BioNTech was little-known internationally and primarily focused on developing novel cancer treatments. The founders were confident in the potential of their mRNA technology, which they knew could trigger a powerful immune response. That confidence wasn’t necessarily shared by the broader medical community. No mRNA vaccine or treatment had ever been approved before. But the couple’s timely breakthrough was actually decades in the making. CNBC spoke with Şahin and Türeci about how they, along with Pfizer, created a Covid-19 vaccine using mRNA.
Molnupiravir (MK-4482, EIDD-2801) is an investigational oral antiviral medicine that significantly reduced the risk of hospitalization or death at a planned interim analysis of the Phase 3 MOVe-OUT trial in at risk, non-hospitalized adult patients with mild-to-moderate COVID-19. At the interim analysis, molnupiravir reduced the risk of hospitalization or death by approximately 50%; 7.3% of patients who received molnupiravir were either hospitalized or died through Day 29 following randomization (28/385), compared with 14.1% of placebo-treated patients (53/377); p=0.0012. Through Day 29, no deaths were reported in patients who received molnupiravir, as compared to 8 deaths in patients who received placebo.
As the FDA nears a decision on authorizing Pfizer’s Covid-19 vaccine for children 5-11 years old, public-health officials and pediatricians are sharing research with families to assure hesitant parents of the shot’s safety. Photo: John Locher/Associated Press
UCSF Health physicians have successfully treated a patient with severe depression by tapping into the specific brain circuit involved in depressive brain patterns and resetting them using the equivalent of a pacemaker for the brain.
Your brain is keenly aware of what’s going on inside your body at all times. Some things are obvious – like when you feel hungry or thirsty. But some things you never notice – like how blood vessels all over your body simultaneously contract as you stand up, so you don’t lose blood flow to your brain. But how does your brain know when to send the signal to squeeze? It’s all part of concept scientists call interoception – the dialogue between your brain and the rest of your body.
Interoception is involved in everything from keeping us balanced while we walk, to keeping our blood pressure and heart rate steady. It even appears to influence our moods and emotions. And thanks to recent discoveries, we’re learning more about how interoception works. Researchers identified two special channels in neurons that react to touch and named them PIEZO1 and PIEZO2. Since first identifying these pressure sensors, researchers have found PIEZOs in internal organs like the heart, lungs, and blood vessels lining the stomach… suggesting many physiological functions involve mechanical forces that our brain and other parts of our nervous system must monitor and influence. As the study of interoception grows, scientists are hopeful the field could lead to breakthroughs in treating heart disease, controlling blood pressure, relieving anxiety and depression, and treating a number of other disorders. Learn more about Scripps Research at scripps.edu.